Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Novo Nordisk has reached the end of its two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for breaches of its code of practice, after showing "significant and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

People hate the chart or whatever — but then you’ll ... LLY), particularly in relation to the competition with Novo Nordisk and its weight-loss drugs at the time. Cramer was enthusiastic ...